IRVINE, Calif., March 2 /PRNewswire-FirstCall/ -- Spectrum Pharmaceuticals, Inc. today announced the appointment of Daniel Pertschuk, M.D., as Vice President of Medical Affairs. In this role, Dr. Pertschuk will oversee the clinical development of Spectrum’s portfolio of oncology-focused drugs. Dr Pertschuk will report directly to Dr. Luigi Lenaz, Chief Scientific Officer.
“We are very excited to have someone of Dr. Pertschuk’s experience and capabilities join the Spectrum team,” stated Rajesh C. Shrotriya, M.D., Chairman, Chief Executive Officer and President of Spectrum Pharmaceuticals, Inc. “He brings to Spectrum a track record of successfully implementing large international survival trials of immunotherapy. His experience and capabilities should prove invaluable, as we move forward, to accelerate and expand our clinical development programs, in particular as our compound Eoquin(TM) moves closer to starting a phase 3 clinical trial.”
“I am delighted to join the Spectrum team, and look forward to helping drive the evolution and growth of Spectrum’s clinical development programs,” said Dr. Pertschuk.
Dr. Pertschuk received his MD degree from the University of Pennsylvania and is Board Certified in Internal and Geriatric Medicine. During the past fifteen years, Dr. Pertschuk has had increasing responsibilities in designing and implementing clinical development programs in a number of different therapeutic areas including oncology.
About Spectrum Pharmaceuticals
Spectrum Pharmaceuticals is a specialty pharmaceutical company engaged in the business of acquiring, developing and commercializing prescription drug products for the treatment of cancer and other unmet medical needs. By leveraging its operational flexibility and regulatory proficiency, and using the extensive research and development capabilities of its strategic alliance partners, Spectrum has built a diversified portfolio of proprietary and generic drug products in various stages of development and regulatory approval. For more information, please visit our website at www.spectrumpharm.com.
Forward-looking statements
This press release may contain forward-looking statements regarding future events and the future performance of Spectrum Pharmaceuticals that involve risks and uncertainties that could cause actual results to differ materially. These statements include but are not limited to statements that relate to our business and its future, the Company’s operational flexibility and regulatory proficiency, the extensive research and development capabilities of the Company’s strategic alliance partners, the experience and capabilities of Dr. Pertschuk to accelerate and expand our clinical development programs, Eoquin(TM) moving closer to a Phase 3 clinical trial, and any statements that relate to the intent, belief, plans or expectations of Spectrum or its management, or that are not a statement of historical fact. Risks that could cause actual results to differ include the possibility that our existing and new drug candidates, may not prove safe or effective, the possibility that our existing and new drug candidates may not receive approval from the FDA, and other regulatory agencies in a timely manner or at all, the possibility that our existing and new drug candidates, if approved, may not be more effective, safer or more cost efficient than competing drugs, the possibility that price and other competitive pressures may make the marketing and sale of our drugs not commercially feasible, the uncertainties involved in and unpredictability of litigation, the possibility that our efforts to acquire or in-license and develop additional drug candidates may fail, our lack of revenues, our limited experience in establishing strategic alliances, our limited marketing experience, our limited experience with the generic drug industry, our dependence on third parties for clinical trials, manufacturing, distribution and quality control and other risks that are described in further detail in the Company’s reports filed with the Securities and Exchange Commission.
Contact: Dr. Rajesh C. Shrotriya Chairman, President and CEO (949) 743-9295
Spectrum Pharmaceuticals, Inc.
CONTACT: Dr. Rajesh C. Shrotriya, Chairman, President and CEO of SpectrumPharmaceuticals, Inc., +1-949-743-9295
Web site: http://www.spectrumpharm.com//
